Real-world laboratory functionality requirements and implementation considerations for fast phenotypic antimicrobial...

Timely and effective antimicrobial therapy is essential for managing bacteremia and reducing associated morbidity and mortality. Fast phenotypic antimicrobial susceptibility testing (fAST) technologies offer the potential to accelerate optimal therapy by providing fast, actionable results. However, real-world adoption of fAST is influenced by laboratory infrastructure, antimicrobial stewardship practices, and the adaptability of new diagnostic platforms. We conducted an Early Evaluation Program (EEP) of the VITEK® REVEAL™ system at 13 U.S. hospital-based microbiology laboratories to assess performance and user experience related to the assay and fAST in general. A survey was performed as a component of the EEP to qualitatively assess barriers and facilitators to fAST implementation. Survey responses highlighted that ease of use, improved turnaround time, and clinical impact were the most valued features of fAST. Willingness to adopt fAST was high, but hesitations centered on evidence gaps, resource constraints, and the need for robust performance data. Key determinants of adoption included patient complexity, laboratory staffing, and workflow integration. Mapping responses to the Consolidated Framework for Implementation Research (CFIR) identified critical domains such as evidence base, adaptability, cost, and communication pathways. Successful implementation strategies included stakeholder education and engagement, consensus-building, and tailoring software to local needs. These findings highlight that while fAST can transform bacteremia management, its impact depends on addressing local barriers, fostering multidisciplinary collaboration, and ensuring ongoing evaluation of clinical and operational outcomes.